Teclistamab Demonstrates Exciting Efficacy in Relapsed or Refractory Multiple Myeloma
February 9th 2023Alfred L. Garfall, MD, discusses the durability of responses teclistamab elicited in the MajesTEC-1 trial and how this agent will change the treatment regimen for relapsed/refractory multiple myeloma.
Read More
Investigators Unpack Potential Role of Nab-Sirolimus for Solid Tumors With TSC1/2 Mutations
January 27th 2023Brian Schulte, MD, discusses the relevance of these mutations and an actively enrolling phase 2 PRECISION-1 basket trial investigating the efficacy of nab-sirolimus in solid tumors.
Read More
Randall Highlights Advances in Reconstruction Techniques for Patients With Bone Sarcomas
December 25th 2022Robert Lawrence Randall, MD, FACS, discussed the role of biological reconstructions as well as factors that determine whether a patient would benefit more from the reconstructions or traditional prosthetics known as endoprosthetics.
Read More
Adagrasib Provides New Option for Patients with KRAS G12C–Mutant NSCLC
December 22nd 2022The FDA’s accelerated approval of adagrasib for adult patients with KRAS G12C–mutated locally advanced or metastatic non–small cell lung cancer who have received at least 1 prior systemic therapy has provided a second KRAS G12C inhibitor option for patients.
Read More
Radiation Therapy Plus Surgery May Improve Local Control in Localized Pelvic Ewing Sarcoma
December 22nd 2022R. Lor Randall, MD, FACS, discusses the significance of addition of surgery to radiation therapy led to improved local control compared with radiation therapy alone in patients with localized pelvic Ewing Sarcoma.
Read More
The CAR-T cell therapy ciltacabtagene autoleucel has expanded options for adult patients with relapsed/refractory multiple myeloma after 4 or more lines of prior therapy in the United States, and has continued to display promising efficacy in patients with multiple myeloma following early relapse.
Read More
Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.
Read More
Adjuvant Nivolumab Displays Real-world Benefits in Resected Stage IIIA Melanoma
November 27th 2022Adjuvant nivolumab produced survival benefits in patients with resected stage IIIA melanoma, where a significant portion of patients were recurrence free at a median follow-up of over 20 months.
Read More
Advances in Breast Cancer Treatment Reshape Treatment Paradigms in 2022
November 21st 2022The increasing role of antibody-drug conjugates have led to questions of sequencing for patients with HER2-positive breast cancer, whereas new data for first-generation PD-L1 inhibitors, such as pembrolizumab have shaken up the treatment paradigm for others.
Read More
Genetic Testing Proves Significant in Identifying Somatic and Germline Mutations in Prostate Cancer
November 11th 2022As the role of genetic testing in clinical practice becomes more prevalent for patients with prostate cancer to identify mutations, physicians must consider a variety of factors to determine which patients are candidates for somatic and/or germline testing.
Read More
Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment
November 10th 2022Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.
Read More